This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Cardiovascular Systems Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

n/a

Temettü verimi

n/a

Ödeme oranı

Sektör ortalama getirisi	1.6%
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Hisse başına kazanç	-US$0.90
Temettü verim tahmini	0%

Son temettü güncellemeleri

Güncelleme yok

Recent updates

We're Not Very Worried About Cardiovascular Systems' (NASDAQ:CSII) Cash Burn Rate

Feb 03

We're Hopeful That Cardiovascular Systems (NASDAQ:CSII) Will Use Its Cash Wisely

Oct 12

Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates

Aug 03

Here's Why Cardiovascular Systems, Inc.'s (NASDAQ:CSII) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 05

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 36%?

Oct 09

At US$36.59, Is It Time To Put Cardiovascular Systems, Inc. (NASDAQ:CSII) On Your Watch List?

Sep 18

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 28%?

Jun 24

Is Now The Time To Look At Buying Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Jun 03

We're Interested To See How Cardiovascular Systems (NASDAQ:CSII) Uses Its Cash Hoard To Grow

Apr 29

Should You Take Comfort From Insider Transactions At Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Mar 17

Cardiovascular Systems (NASDAQ:CSII) Shareholders Have Enjoyed A Whopping 399% Share Price Gain

Feb 10

Cardiovascular Systems misses on revenue

Feb 03

Need To Know: Cardiovascular Systems, Inc. (NASDAQ:CSII) Insiders Have Been Selling Shares

Dec 11

Cardiovascular Systems, Inc. 2021 Q1 - Results - Earnings Call Presentation

Nov 06

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: Insufficient data to determine if CSII's dividends per share have been stable in the past.

Büyüyen Temettü: Insufficient data to determine if CSII's dividend payments have been increasing.

Piyasaya Karşı Temettü Getirisi

Cardiovascular Systems Piyasaya Karşı Temettü Getirisi

CSII temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (CSII)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.4%
Sektör Ortalaması (Medical Equipment)	1.6%
Analist tahmini (CSII) (3 yıla kadar)	0%

Önemli Temettü: Unable to evaluate CSII's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Yüksek Temettü: Unable to evaluate CSII's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as CSII has not reported any payouts.

This company has been acquired

Cardiovascular Systems Temettü

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü güncellemeleri

Recent updates

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Abbott Laboratories (NYSE:ABT) entered into a definitive agreement to acquire Cardiovascular Systems, Inc. (NasdaqGS:CSII) for approximately $880 million.

We're Not Very Worried About Cardiovascular Systems' (NASDAQ:CSII) Cash Burn Rate

Cardiovascular Systems, Inc. to Report Q2, 2023 Results on Feb 09, 2023

Cardiovascular Systems, Inc. Enrolls First Patient in Japan for Kaizen Clinical Study

Price target decreased to US$21.20

Insufficient new directors

First quarter 2023 earnings: EPS misses analyst expectations

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Year Ending June 30, 2023

Cardiovascular Systems, Inc. Announces Full Market Release of the 2.00 Max Crown for Peripheral Orbital Atherectomy Systems

Cardiovascular Systems, Inc. to Report Q1, 2023 Results on Nov 03, 2022

We're Hopeful That Cardiovascular Systems (NASDAQ:CSII) Will Use Its Cash Wisely

Cardiovascular Systems, Inc., Annual General Meeting, Nov 08, 2022

Full year 2022 earnings: EPS misses analyst expectations

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Year Ending June 30, 2023

Cardiovascular Systems reports Q4 earnings miss; provides FY23 revenue guidance in-line with estimates

Cardiovascular Systems, Inc. to Report Q4, 2022 Results on Aug 02, 2022

Cardiovascular Systems, Inc.(NasdaqGS:CSII) dropped from Russell 2000 Growth-Defensive Index

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Price target decreased to US$23.50

Cardiovascular Systems, Inc. to Report Q3, 2022 Results on May 04, 2022

Cardiovascular Systems, Inc. Announces Ryan Egeland Employment Would End as Chief Medical Officer

Consensus revenue estimates fall by 10%

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fiscal Year Ending June 30, 2022

Cardiovascular Systems, Inc. Along with Orbusneich Medical Company Ltd, Announces FDA PMA Approval of Orbusneich’s Scoreflex®NC Scoring Percutaneous Transluminal Coronary Angioplasty Catheter

Cardiovascular Systems, Inc. Announces Development of Intravascular Lithotripsy Technology for the Treatment of Coronary and Peripheral Artery Diseases

No longer forecast to breakeven

First quarter 2022 earnings released: US$0.22 loss per share (vs US$0.054 loss in 1Q 2021)

Price target decreased to US$41.50

Here's Why Cardiovascular Systems, Inc.'s (NASDAQ:CSII) CEO Compensation Is The Least Of Shareholders' Concerns

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 36%?

Cardiovascular Systems, Inc. Announces First Patient Treated with ViperCross Peripheral Support Catheter

At US$36.59, Is It Time To Put Cardiovascular Systems, Inc. (NASDAQ:CSII) On Your Watch List?

Consensus forecasts updated

Consensus forecasts updated

Full year 2021 earnings released: US$0.35 loss per share (vs US$0.80 loss in FY 2020)

Are Investors Undervaluing Cardiovascular Systems, Inc. (NASDAQ:CSII) By 28%?

Is Now The Time To Look At Buying Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Cardiovascular Systems, Inc. Announces U.S. Commercial Launch of JADE Over-the-Wire Non-Compliant Peripheral Balloon Catheters

Cardiovascular Systems, Inc Announces Results from a Real-World Optical Coherence Tomography

Independent Director recently bought US$52k worth of stock

Cardiovascular Systems, Inc. Provides Earnings Guidance for the Fourth Quarter Ending June 30, 2021

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.085 loss in 3Q 2020)

We're Interested To See How Cardiovascular Systems (NASDAQ:CSII) Uses Its Cash Hoard To Grow

Cardiovascular Systems, Inc. Announces First Uses of WIRION® Embolic Protection System

Should You Take Comfort From Insider Transactions At Cardiovascular Systems, Inc. (NASDAQ:CSII)?

Cardiovascular Systems (NASDAQ:CSII) Shareholders Have Enjoyed A Whopping 399% Share Price Gain

First Patient in Europe Treated With Cardiovascular Systems, Inc. Diamondback 360® Coronary Orbital Atherectomy System

Earnings beat expectations, revenue disappoints

Second quarter 2021 earnings released: US$0.001 loss per share (vs US$0.10 loss in 2Q 2020)

Cardiovascular Systems misses on revenue

Cardiovascular Systems, Inc. Announces Partnership with Chansu Vascular Techologies, Llc to Develop New Drug-Coated Balloon Technology

Cardiovascular Systems, Inc. Elects Sachin Jain as a Class II Director

New 90-day high: US$46.79

Cardiovascular Systems, Inc. to Report Q2, 2021 Results on Feb 03, 2021

New 90-day high: US$44.30

New 90-day high: US$39.84

Need To Know: Cardiovascular Systems, Inc. (NASDAQ:CSII) Insiders Have Been Selling Shares

Analysts update estimates

Cardiovascular Systems, Inc. 2021 Q1 - Results - Earnings Call Presentation

Revenue beats expectations, earnings disappoint

First quarter 2021 earnings released: US$0.054 loss per share

Cardiovascular Systems to Present Data from Large Coronary Orbital Atherectomy Study at the TCT Connect 2020 Conference

New 90-day high: US$39.35

Cardiovascular Systems Inc. signed a definitive agreement to acquire Replidyne, Inc. (NasdaqGM: RDYN) in a reverse merger transaction.

New 90-day high - US$34.99

Full year earnings released - US$0.79 loss per share

Independent Director recently bought US$97k worth of stock

Full year earnings released - US$0.79 loss per share

Cardiovascular Systems, Inc. to Report Q4, 2020 Results on Aug 04, 2020

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi